{"title":"Development of pH-responsive Mucoadhesive Nanohybrids of Eudragit-Ziziphus for Colonic Delivery of Quercetin-Lactobacillus plantarum in Inflammatory Bowel Disease","authors":"Priyanka Ray, Subhrajyoti Dhara, Subhojit Panja","doi":"10.1007/s12247-026-11076-x","DOIUrl":"10.1007/s12247-026-11076-x","url":null,"abstract":"<div><h3>Background</h3><p>Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract associated with oxidative stress and gut microbiota imbalance. This study aimed to develop a pH-responsive, mucoadhesive nanohybrid system incorporating quercetin and <i>Lactobacillus plantarum</i> for targeted colonic delivery.</p><h3>Methods</h3><p>Quercetin-loaded solid lipid nanoparticles were formulated using glyceryl monostearate and a lecithin–cholesterol combination. The formulations were coated with Ziziphus gum and Eudragit S100 to confer mucoadhesive and colon-targeting properties. The system was characterized using FTIR, DLS, zeta potential analysis, SEM, and XRD, and evaluated for encapsulation efficiency, probiotic viability, antioxidant activity, drug release, and mucoadhesion.</p><h3>Results</h3><p>The optimized formulation exhibited a particle size of 330.90 ± 1.21 nm, a polydispersity index (PDI) of 0.402, a zeta potential of −13 mV, and an encapsulation efficiency of 75.56%. Probiotic viability was maintained at 1.1 × 10⁸ CFU/mL. FTIR and XRD confirmed successful quercetin incorporation, while SEM revealed nanosized particles distributed within a polymeric matrix. The formulation demonstrated antioxidant activity (IC50 = 142.6 µg/mL) and pH-responsive drug release, with 10.94%, 51.56%, and 87.48% release at pH 1.2, 6.8, and 7.4, respectively. A bioadhesive force of 0.556 N indicated good mucoadhesive strength.</p><h3>Conclusion</h3><p>The Eudragit–Ziziphus-coated quercetin–probiotic nanohybrid system demonstrated controlled, pH-responsive drug release, sustained antioxidant activity, and effective probiotic protection, supporting its potential as a colon-targeted delivery strategy for the localized treatment of IBD.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Development and Evaluation of Palbociclib Nanocrystals Using a Quality by Design Approach: In Silico, In Vitro, and In Vivo Pharmacokinetic Studies","authors":"Trupti Powar, Ashok Hajare, Sopan Nangare","doi":"10.1007/s12247-026-11092-x","DOIUrl":"10.1007/s12247-026-11092-x","url":null,"abstract":"<div><p>This study aimed to develop lyophilized palbociclib nanocrystals (PALB-NPs) with enhanced oral bioavailability using a Quality by Design (QbD)-based approach. A Plackett-Burman (PB) design was employed to investigate the influence of various process and formulation variables on the development of PALB-NPs. Among the investigated variables, high-pressure homogenization (HPH) cycles, concentration of soya lecithin, and concentration of poloxamer 407 were identified as critical factors and subsequently optimized using a Central Composite Design (CCD). The optimized lyophilized PALB-NPs exhibited a particle size of 269 ± 0.19 nm, drug content (DC) of 88.45 ± 0.48%, and entrapment efficiency (EE) of 98.98 ± 0.45%. SEM analysis revealed a uniform rod-shaped morphology of PALB-NPs. In vitro cytotoxicity studies demonstrated significantly enhanced anticancer activity, with IC50 values of 26.45 µg/mL for PALB-NPs and 65.4 µg/mL for PALB-aqueous dispersion (AQD). The dissolution study showed improvement in drug release, with dissolution rates of 96.366 ± 0.015% for PALB-NPs compared to 43.201 ± 0.025% for pure PALB within 60 min. Furthermore, pharmacokinetic studies revealed 1.77-fold and 2.38-fold increases in C<sub>max</sub> and AUC<sub>0−</sub>t, respectively, for PALB-NPs compared with PALB-AQD. The relative bioavailability of PALB-NPs was found to be 2.24 ± 1.32, with higher drug accumulation observed in the liver during biodistribution studies. Overall, QbD-optimized lyophilized PALB-NPs demonstrated improved dissolution, enhanced oral bioavailability, favorable stability, and enhanced cytotoxic activity against MCF-7 cells. Keywords: Breast cancer, Palbociclib, Nanocrystal, Quality-by-Design approach, Lyophilisates, Bioavailability, In vitro cytotoxicity.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Global Regulatory Pathways for 3D-Printed Medical Devices: Comparative Analysis of US, EU, India, Japan, and Australia with Market Insights","authors":"Priyal Desai, Charmy S. Kothari","doi":"10.1007/s12247-026-11090-z","DOIUrl":"10.1007/s12247-026-11090-z","url":null,"abstract":"<div><h3>Purpose</h3><p>3D printing technology is being used extensively for medical devices including orthopaedic implants, cranial implants, dental restorations, and surgical instruments. Also, the development of global regulatory pathways governing these 3D printed medical devices have been evolving to meet the global regulations. Further, market analysis scrutinizes the growing need of 3D printed medical devices. This article aims to help define the regulatory pathways and commercial aspects of 3D printed medical devices in the current healthcare delivery system.</p><h3>Methods</h3><p>This review covers primarily the regulatory pathways available for 3D printed medical devices across United States, European Union, India, Japan and Australia, an analysis of the current and projected 3D printing market size and trends (2022–2035), and representative examples of case studies that demonstrate these elements.</p><h3>Results</h3><p>The 3D printing technology regulations vary significantly across United States, European Union, India, Japan and Australia. The regulatory bodies of United States and Australia have shown considerable advancement in regulations, while others are still emerging. Published market estimates coverage on a compound annual growth rate (CAGR) of approximately 17%.</p><h3>Conclusion</h3><p>Regulatory compliance requires manufacturers to follow strict, region-specific standards set forth by relevant agencies and to meet these, manufacturers must established robust quality management system and validate regulatory pathways.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Earthworm as a Sustainable Bioreactor: Biotransformed Nigella sativa Metabolites as Potential Dual Modulators of HDAC2 and BCL2 for HIV Latency: An Integrated Computational and Zebrafish Study","authors":"Kamardeen Shimar Mohamed Yasin, Arockiya Anita Margret, Chrisanne Freeman","doi":"10.1007/s12247-026-11075-y","DOIUrl":"10.1007/s12247-026-11075-y","url":null,"abstract":"<div><p>Earthworm-mediated biotransformation offers a sustainable strategy to enhance the biological potential of natural products through the generation of structurally modified bioactive metabolites. In this study, <i>Eisenia fetida</i> was employed as a living bioreactor to biotransform <i>Nigella sativa</i> (black cumin), and the resulting methanolic extracts were evaluated using integrated experimental and computational approaches. GC–MS profiling revealed distinct alterations in the metabolite composition of the black cumin-fed earthworm extract compared with the kitchen waste-fed control, indicating the formation of biotransformed metabolites. The biotransformed extract exhibited enhanced antioxidant, anti-inflammatory and erythrocyte membrane-stabilizing activities, together with selective antibacterial activity against <i>Staphylococcus aureus</i> and antifungal activity against <i>Aspergillus niger</i>. Zebrafish (<i>Danio rerio</i>) embryo toxicity assays demonstrated concentration-dependent developmental toxicity, with the bio-transformed extract exhibiting a higher median lethal concentration (LC₅₀ = 229.89 µg/mL) than the control extract (LC₅₀ = 147.10 µg/mL), indicating improved embryonic biocompatibility following earthworm-mediated biotransformation. Network pharmacology identified HDAC2 and BCL2 as key host proteins associated with HIV latency, epigenetic regulation and apoptosis. Molecular docking predicted favourable interactions of Benzoic acid, 3-formyl-2,4-dihydroxy-6-methyl-, methyl ester, identified as the prominent bio-transformed metabolite, exhibited favourable binding to HDAC2 (− 8.16 kcal mol⁻¹) and BCL2 (− 6.75 kcal mol⁻¹), supporting it as a putative as a dual-target candidate and provide a hypothesis for further experimental investigation, rather than demonstrating direct target modulation. Collectively, these findings indicate that earthworm-mediated biotransformation enhances both the biological activity and safety profile of <i>N. sativa</i>, highlighting the potential of earthworms as sustainable living bioreactors for generating novel metabolites with promising therapeutic applications in HIV latency and associated pathways. </p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149133391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hassan Ayaz, Ayesha Zahid, Adnan Zeb, Faisal Ahmad, Nazish Badar, Dalia M Alammari, Eid A. Alatawi, Sajjad Ahmad, Fahad M Alshabrmi, Taghreed N. Almanaa
{"title":"Molecular Design of Novel mRNA and Multiepitope Subunit Vaccines for H10N5 Avian Influenza A virus","authors":"Hassan Ayaz, Ayesha Zahid, Adnan Zeb, Faisal Ahmad, Nazish Badar, Dalia M Alammari, Eid A. Alatawi, Sajjad Ahmad, Fahad M Alshabrmi, Taghreed N. Almanaa","doi":"10.1007/s12247-026-11081-0","DOIUrl":"10.1007/s12247-026-11081-0","url":null,"abstract":"<div><h3>Background</h3><p>Annually, influenza viruses cause a considerable number of deaths worldwide and are a primary cause of severe respiratory diseases. Finding novel immunogenic locations that might trigger a potent immune response is therefore crucial.</p><h3>Methods</h3><p>The present study utilized bioinformatics techniques to develop mRNA and multiepitope-based vaccines that specifically target the H10N5 Avian Influenza A virus. The epitopes of the hemagglutinin (HA) and neuraminidase (NA) proteins on T and B cells of this specific strain were identified using a variety of immunoinformatic techniques. The chosen HTL epitopes and their corresponding major histocompatibility complex (MHC) alleles were docked by using a molecular docking technique.</p><h3>Results</h3><p>A total of 6 linear B cell epitopes, 6 HTL epitopes, and 6 CTL epitopes were chosen for the structural design of preventive vaccines based on mRNA and multiepitope subunit. At physiological pH the developed vaccines demonstrated strong antigenicity, little toxicity, and non-allergenic qualities. The generated multiepitope subunit vaccine for Flu GC content and CAI value, which were determined to be 49.41% and 0.975%, respectively, were assessed using the codon optimization tool. The stable expression of the vaccine in the pET28aþ vector is confirmed by the GC content and CAI value. A significant degree of immune responses was found by in silico immunological simulation. The top ranked docking pose (HDOCK model 3) from ten models was subjected to 100 ns all-atom MD simulation in AMBER22 with the ff19SB force field in explicit OPC water. An average of 6.8 inter-chain hydrogen bonds, in addition to favourable short-range Coulomb (− 1,032 kJ/mol) and Lennard-Jones (− 436 kJ/mol) interaction energies, continued to maintain contact between the interfaces. Using molecular mechanics/Poisson–Boltzmann surface area (MM/PBSA) and molecular mechanics/generalized Born surface area (MM/GBSA) methods, the calculated free energies are ΔGbind of − 83.30 ± 29.20 and − 94.72 ± 29.41 kcal/mol, respectively, and the residues Lys381, Arg569, Lys396, Glu237, and Glu527 are identified as the leading contributors to the binding free energy. Thus, the constructed vaccine against avian influenza H10N5 A viral strain showed high potential.</p><h3>Conclusion</h3><p>The vaccine candidate demonstrated promising computational characteristics and requires experimental validation.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149133344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xinxin Xu, Penghui Shi, Yingchao Wang, Hongmei Yan
{"title":"Methotrexate Loaded Zinc Oxide/Indigo naturalis Nanocomposite Hydrogel Attenuates Imiquimod-induced Psoriasis Via Suppression of Inflammation, Regulation of Apoptosis, and Inhibition of NF-κB/MAPK Signaling Pathways","authors":"Xinxin Xu, Penghui Shi, Yingchao Wang, Hongmei Yan","doi":"10.1007/s12247-026-11037-4","DOIUrl":"10.1007/s12247-026-11037-4","url":null,"abstract":"<div><h3>Background</h3><p>Psoriasis is a multifactorial chronic inflammatory skin disorder driven by immune system dysregulation, uncontrolled keratinocyte proliferation, and the interconnected inflammatory signaling cascades activation, resulting in pathological skin remodeling and persistent epidermal inflammation. Although methotrexate (MTX) remains a first-line remedial agent for severe-to-moderate psoriasis, its long-term clinical use is limited by poor target specificity, systemic adverse effects, and frequent disease recurrence. Nanocomposite-based drug delivery systems have emerged as promising remedial strategies to increase localized drug delivery, ameliorate remedial efficacy, and decrease systemic toxicity.</p><h3>Objective</h3><p>This research aimed to develop and characterize a methotrexate-loaded zinc oxide/Indigo naturalis-chitosan (MTX/ZnO/IN) nanocomposite hydrogel and assess its anti-psoriatic potential and underlying molecular mechanisms. The novelty of this study lies in the integration of MTX with ZnO and Indigo naturalis within a chitosan-based nanocomposite hydrogel, combined with comprehensive evaluation of preclinical, histopathological, inflammatory, apoptotic, and signaling responses.</p><h3>Methods</h3><p>The MTX/ZnO/IN nanocomposite hydrogel was characterized by FE-SEM, FT-IR, EDX, UV-Vis spectroscopy, and XRD analyses. The characterization outcomes confirmed the successful incorporation of MTX, ZnO, and IN within the hydrogel matrix, demonstrating the desired morphology, optical properties, chemical composition, and crystalline structure of the nanocomposite hydrogel. The anti-inflammatory activity of the MTX/ZnO/IN nanocomposite hydrogel was determined by quantifying the expression levels of key pro-inflammatory cytokines, including TNF-α, IL-1β, IL-17, and IFN-γ, using ELISA. In addition, the regulatory effects of the nanocomposite hydrogel on apoptosis-related proteins (Bcl-2 and Bax) and major components involved in the NF-κB and MAPK signaling pathways were assessed through Western blotting and qRT-PCR analyses. In addition, a psoriasis BALB/c mouse model was established to assess the in vivo remedial effect of MTX/ZnO/IN through evaluation of PASI scores, inflammatory biomarkers, histopathological alterations, and molecular signaling pathways.</p><h3>Results</h3><p>Treatment with MTX/ZnO/IN significantly improved psoriasis-like skin lesions by decreasing PASI scores, epidermal hyperplasia, erythema, scaling, and inflammatory cell infiltration. The MTX/ZnO/IN nanocomposite hydrogel markedly suppressed the production of IL-1β, IL-17, TNF-α, and IFN-γ, downregulated the Cyr61 and ICAM-1 expression, restored the balance between apoptotic genes, and prevented activation of the MAPK and NF-κB signaling pathways. These outcomes reveal that MTX/ZnO/IN effectively suppresses inflammatory responses through regulation of apoptosis and inflammatory signaling cascades.</p><h3>Conclusion</h3><p>MTX/ZnO/IN nanocomposite hyd","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149133194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shahad W. Kattan, Alhanouf I. Al-Harbi, Bian K. Almessiry, Hanadi Talal Ahmedah, Sara H. Mokhtar, Ekramy M. Elmorsy, Mona M. Elghareeb
{"title":"Chrysin-Loaded Casein Nanoparticles Protect Against Sepsis-Associated Acute Kidney Injury via Activation of Nrf2/HO-1 and Suppression of TLR4/NF-κB Signaling","authors":"Shahad W. Kattan, Alhanouf I. Al-Harbi, Bian K. Almessiry, Hanadi Talal Ahmedah, Sara H. Mokhtar, Ekramy M. Elmorsy, Mona M. Elghareeb","doi":"10.1007/s12247-026-11079-8","DOIUrl":"10.1007/s12247-026-11079-8","url":null,"abstract":"<div><h3>Background</h3><p>Chrysin, a natural flavonoid with potent antioxidant and anti-inflammatory activities, is clinically limited by poor aqueous solubility and low oral bioavailability, necessitating advanced delivery strategies. Sepsis-induced acute kidney injury (AKI) remains a life-threatening condition with limited therapeutic interventions. This study aimed to develop and characterize a novel casein-based nanoparticulate delivery system (Chry-Cas-NPs) to enhance the oral bioavailability and therapeutic efficacy of chrysin.</p><h3>Methods</h3><p>Sixty male Sprague Dawley rats were randomly assigned to six groups, including controls, lipopolysaccharide (LPS)-exposed animals, and LPS-treated groups receiving crude chrysin (Chry) or Chry-Cas-NPs. The optimized nanoformulation was characterized for encapsulation efficiency, drug release, and physicochemical stability. Renal function, oxidative stress, inflammatory responses, iron accumulation, apoptosis, histopathology, and pharmacokinetic parameters were evaluated.</p><h3>Results</h3><p>The optimized nanoformulation demonstrated high encapsulation efficiency, controlled and sustained drug release, and excellent physicochemical stability, supporting its suitability as an oral nanocarrier system. LPS administration significantly impaired renal function, as evidenced by elevated serum urea, creatinine, uric acid, and kidney injury molecule-1. Oxidative stress was markedly increased, with suppression of Nrf2/HO-1 signaling, depletion of SOD, CAT, and GSH, and elevation of MDA and 8-hydroxy-2′-deoxyguanosine. Inflammatory injury was characterized by activation of TLR4/NF-κB signaling, upregulation of COX-2, and increased TNF-α, IL-6, IL-1β, nitric oxide, prostaglandin E2, and myeloperoxidase. LPS also induced renal iron accumulation and apoptosis, reflected by increased Bax, caspase-3, and caspase-8, with reduced Bcl-2 expression. Importantly, nanoencapsulation significantly enhanced systemic exposure of chrysin, demonstrating improved pharmacokinetic behavior compared to the free drug. Treatment with Chry-Cas-NPs significantly restored renal function, attenuated oxidative and inflammatory injury, reduced apoptosis, and preserved renal architecture, exhibiting superior therapeutic efficacy relative to crude chrysin due to improved bioavailability and sustained drug release. Mechanistically, the enhanced reno protective effect of Chry-Cas-NPs is attributed to efficient delivery and activation of Nrf2/HO-1 antioxidant pathways alongside suppression of TLR4/NF-κB-mediated inflammatory signaling.</p><h3>Conclusion</h3><p>Collectively, this study highlights casein-based nanoparticles as a promising, biocompatible oral delivery platform for poorly soluble flavonoids and supports their potential for translational development in the management of sepsis-associated AKI.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149133193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Waqar Ahmad, Xinyi Zhu, Shahin Shah Khan, Yi Bai, Pengfei Pei
{"title":"Machine Learning–Based QSAR Screening of Natural Product and ZINC Libraries Uncovers Stable BACE-1 Inhibitors Validated by Gaussian Accelerated Molecular Dynamics (GaMD) Simulations","authors":"Waqar Ahmad, Xinyi Zhu, Shahin Shah Khan, Yi Bai, Pengfei Pei","doi":"10.1007/s12247-026-11068-x","DOIUrl":"10.1007/s12247-026-11068-x","url":null,"abstract":"<div><p>Beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1) plays a central role in amyloid-β production and remains an important therapeutic target for Alzheimer’s disease. This study developed an integrated quantitative structure–activity relationship and molecular dynamics (QSAR–MD) framework to identify promising BACE-1 inhibitor candidates. From 15,642 initially retrieved bioactivity records, 5,245 remained after preprocessing, and 5,235 compounds with complete fingerprint data constituted the final QSAR dataset. Random Forest models based on twelve molecular fingerprint classes were benchmarked against AdaBoost, Gradient Boosting, and XGBoost using identical training and external-validation sets. CDK and CDK Extended fingerprints produced the highest validation performance (Q²CV = 0.78 ± 0.03; Q²EXT = 0.79 ± 0.01), while PubChem, MACCS, Klekota–Roth, and Substructure Count fingerprints yielded Q²EXT values of approximately 0.76–0.78. Model reliability was assessed using RMSE, MAE, Y-randomization, applicability-domain analysis, and SHAP interpretation. The selected CDK Extended RF model was applied to the ZINC and NPASS libraries, resulting in five prioritized candidates. Molecular docking indicated favorable interactions with key BACE-1 residues, including the catalytic dyad Asp32 and Asp228 and active-site residues Thr72 and Thr231. Analysis of 200 ns GaMD trajectories using RMSD, RMSF, radius of gyration, SASA, and PCA supported the overall structural stability of the complexes. MM/GBSA analysis identified NPC475168 as the most favorable candidate, with an estimated binding energy of − 64.84 kcal/mol. NPC313966, NPC252056, and NPC471858 also demonstrated favorable dynamic and energetic profiles relative to CNP520. Overall, NPC475168 emerged as the leading computational candidate, although experimental validation, selectivity profiling, and ADMET assessment remain necessary.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149133321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Intranasal Delivery of a Novel Pterostilbene-Phosphatidylcholine Nanosuspension (PTE-PL) Ameliorates Depression like Behavior in Chronic Mild Stress Rats","authors":"Sunita Bhise, Pratiksha Dudhbhate, Sagri Mane, Urmila Aswar","doi":"10.1007/s12247-026-11065-0","DOIUrl":"10.1007/s12247-026-11065-0","url":null,"abstract":"<div><h3>Purpose</h3><p>Pterostilbene (PTE), a natural stilbenoid, possesses potent anti-inflammatory and neuroprotective properties; however, its clinical translation is severely hindered by poor aqueous solubility (0.011 mg/mL), rapid metabolism, and limited oral bioavailability.</p><h3>Method</h3><p>To circumvent these barriers, we have developed an optimized intranasal nanosuspension (PTE-PL) of a pterostilbene-phosphatidylcholine complex (PTE-PC90H), designed for direct nose-to-brain delivery. The formulation was systematically optimized using a Box–Behnken experimental design to achieve ideal particle size and complexation efficiency. The formulation was further assessed for in vivo pharmacokinetic profiling, followed by its evaluation in chronic mild stress (CMS)-induced depression in rats.</p><h3>Results</h3><p>The optimized formulation, featuring a drug-to-lipid-to-surfactant ratio of 1:2:1, yielded a stable nanosuspension with a mean particle size of 241.43 ± 11.82 nm, a zeta potential of -21.98 ± 1.93 mV, and a complexation efficiency of 97.12 ± 1.71%. This formulation achieved a 5-fold increase in aqueous solubility and a 6-fold enhancement in trans-mucosal flux, across sheep nasal mucosa compared to plain PTE. The study revealed that intranasal (i.n.) PTE-PL reached peak plasma concentrations twice as fast as oral PTE, with a 12-fold increase in systemic bioavailability and an 80% improvement in brain targeting efficiency. In a CMS model in rats, intranasal PTE-PL (100 µg, i.n.) significantly reversed behavioral deficits (<i>p</i> < 0.001), as measured by sucrose preference, locomotor activity, and forced swim tests. These behavioral improvements were underpinned by a robust biochemical response, including the restoration of monoamine and BDNF levels, enhancement of antioxidant defenses, and significant attenuation of cortisol, NLRP3, and NF-κB inflammatory pathways (<i>p</i> < 0.001). Histopathological evaluation via Nissl staining confirmed neuroprotection of hippocampal neurons, while H&E staining indicated no adverse nasal epithelial alterations.</p><h3>Conclusion</h3><p>This study demonstrated that the PTE-PL nanosuspension is a highly efficient, non-invasive, and neuroprotective delivery platform, offering a potential therapeutic strategy for the management of clinical depression.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149133324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Analytical Box-Behnken Design Approach for Method Optimization and Validation for Concurrent Determination of Doxecitine and Doxribtimine by RP-HPLC in Bulk and Powder Dosage Form With Degradation Assessment","authors":"Anusha Gandi, Vasanthi Majji, Priyanka Paila, Srinivasa Rao Yarguntla","doi":"10.1007/s12247-026-11062-3","DOIUrl":"10.1007/s12247-026-11062-3","url":null,"abstract":"<div><h3>Purpose</h3><p>The goal of the present research was to create, refine, and validate a stability-indicating isocratic RP-HPLC technique based on AQbD for concurrent measurement of Doxecitine and Doxribtimine in pharmaceutical powder dosage form and bulk medications, with a AQbD approach utilizing a Box–Behnken Design was applied for chromatographic method optimization.</p><h3>Method</h3><p>Optimization was performed by selecting critical method variables like flow rate, the quantity of acetonitrile, and a volume of 0.1% perchloric acid as independent variables, while determining responses such as tailing factor along with retention time. Using mobile phase 0.1% acetonitrile and 30:70 % v/v perchloric acid with a 1.0 mL/min flow rate, a standard chromatographic differentiation was achieved on a X-Terra RP-18 column (250 × 4.6 mm, 5 µm, Waters) with detection at 249 nm and a runtime of 7 minutes. </p><h3>Result</h3><p>For Doxecitine and Doxribtimine, the retention times were determined to be roughly 2.52 and 4.73 minutes, respectively. With correlation values (r²) of 0.999 for the two analytes, the technique demonstrated outstanding linearity. According to ICH requirements, parameters such as system suitability, linearity, precision, specificity, accuracy, robustness, LOQ and LOD were determined to be within acceptable bounds. Studies on forced degradation verified the technique’s capability to indicate stability.</p><h3>Conclusion</h3><p>The established RP-HPLC technique based on AQbD provides a suitable approach for the simultaneous determination and stability testing of Doxecitine and Doxribtimine in pharmaceutical formulation, contributing significantly to the method optimization and regulatory compliance in pharmaceutical analysis.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149133322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}